Merck
  • Home
  • Search Results
  • Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.

Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.

The American journal of pathology (2014-06-21)
Matias Knuuttila, Emrah Yatkin, Jenny Kallio, Saija Savolainen, Teemu D Laajala, Tero Aittokallio, Riikka Oksala, Merja Häkkinen, Pekka Keski-Rahkonen, Seppo Auriola, Matti Poutanen, Sari Mäkelä
ABSTRACT

Androgens are key factors involved in the development and progression of prostate cancer (PCa), and PCa growth can be suppressed by androgen deprivation therapy. In a considerable proportion of men receiving androgen deprivation therapy, however, PCa progresses to castration-resistant PCa (CRPC), making the development of efficient therapies challenging. We used an orthotopic VCaP human PCa xenograft model to study cellular and molecular changes in tumors after androgen deprivation therapy (castration). Tumor growth was monitored through weekly serum prostate-specific antigen measurements, and mice with recurrent tumors after castration were randomized to treatment groups. Serum prostate-specific antigen concentrations showed significant correlation with tumor volume. Castration-resistant tumors retained concentrations of intratumoral androgen (androstenedione, testosterone, and 5α-dihydrotestosterone) at levels similar to tumors growing in intact hosts. Accordingly, castration induced up-regulation of enzymes involved in androgen synthesis (CYP17A1, AKR1C3, and HSD17B6), as well as expression of full-length androgen receptor (AR) and AR splice variants (AR-V1 and AR-V7). Furthermore, AR target gene expression was maintained in castration-resistant xenografts. The AR antagonists enzalutamide (MDV3100) and ARN-509 suppressed PSA production of castration-resistant tumors, confirming the androgen dependency of these tumors. Taken together, the findings demonstrate that our VCaP xenograft model exhibits the key characteristics of clinical CRPC and thus provides a valuable tool for identifying druggable targets and for testing therapeutic strategies targeting AR signaling in CRPC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
α-D-Glucose, anhydrous, 96%
Sigma-Aldrich
Glucose solution, BioUltra, for molecular biology, ~20% in H2O
Isoflurane, European Pharmacopoeia (EP) Reference Standard
Carprofen for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium deoxycholate, ≥97% (titration)
Sigma-Aldrich
D-(+)-Glucose solution, 45% in H2O, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
D-(+)-Glucose solution, 100 g/L in H2O, sterile-filtered, BioXtra, suitable for cell culture
Supelco
D-(+)-Glucose solution, 1 mg/mL in 0.1% benzoic acid, standard for enzymatic assay kits GAGO20, GAHK20, STA20, analytical standard
Sigma-Aldrich
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
L-Lysine monohydrochloride, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
Sodium deoxycholate, BioXtra, ≥98.0% (dry matter, NT)
Sigma-Aldrich
L-Lysine monohydrochloride, BioUltra, ≥99.5% (AT)
Supelco
N,N-Dimethylacetamide, analytical standard
Sigma-Aldrich
N,N-Dimethylacetamide, suitable for peptide synthesis, ≥99.8% (GC)
Supelco
L-Lysine monohydrochloride, certified reference material, TraceCERT®
Supelco
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
N,N-Dimethylacetamide, suitable for HPLC, ≥99.9%
Sigma-Aldrich
N,N-Dimethylacetamide, spectrophotometric grade, ≥99%
Supelco
Carprofen, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
N,N-Dimethylacetamide, puriss. p.a., ≥99.5% (GC)
Sigma-Aldrich
N,N-Dimethylacetamide, ReagentPlus®, 99%
SAFC
N,N-Dimethylacetamide
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
SAFC
Sodium deoxycholate
Carprofen, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
N,N-Dimethylacetamide-d9, 99 atom % D
Sigma-Aldrich
N,N-Dimethylacetamide, ReagentPlus®, ≥99%
Sigma-Aldrich
N,N-Dimethylacetamide, anhydrous, 99.8%
Supelco
Carprofen, VETRANAL®, analytical standard
Supelco
L-Lysine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard